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Abstract 
 
Prior research has indicated a crucial role for apoptotic signaling in skeletal muscle cell 
differentiation. Although a number of caspases (-3, -8, -9) have been implicated in this 
process, few prior investigations have identified a role for the most enigmatic member of 
the caspase family, caspase-2. Due to its unique nuclear localization as well as its 
purported roles in cell cycle regulation and DNA damage response; caspase-2 is a likely 
candidate for regulating differentiation. In order to examine the role of caspase-2 in 
myocyte differentiation, we assessed enzyme activity throughout the time course of 
C2C12 differentiation. Additionally, we stably transfected C2C12 cells with caspase-2 
shRNA to assess the impact of a caspase-2 knockdown on myocyte differentiation. 
Finally, we identified the subcellular localization of caspase-2 and p21 throughout the 
early stages of differentiation. Enzyme activity of caspase-2 transiently increased more 
than two-fold within 24 hours of differentiation induction, with levels returning to normal 
by day 7, indicating that the enzyme likely plays a role in the differentiation process. 
Furthermore, knockdown of caspase-2 dramatically impaired myotube formation and 
induction of cell cycle inhibitor p21 and myogenic regulatory factor myogenin. Caspase-
3 activity was also ablated in the caspase-2 knockdown C2C12 cells. Finally, subcellular 
fractionation of C2C12 cells at early time points in differentiation revealed a nuclear 
retention of both caspase-2 and p21 throughout the process. Given the nuclear 
localization of caspase-2 and p21 as well as the impairment in p21 induction in caspase-2 
KD cells, we propose that the role of caspase-2 in myocyte differentiation is to regulate 
p21 induction at the onset of differentiation. Collectively, the results of this study 
highlight a novel function for caspase-2 in regulating myocyte differentiation.  
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 1 
Introduction 
 
A complex multicellular organism is made up of a variety of tissues and cell 
types, each with their own distinct characteristics and functions. Every single cell in such 
an organism is derived from a single fertilized oocyte that must divide and transform into 
different cell populations (1). Cells that have the capacity to divide, self-maintain, and 
mature into specialized cell types are known as stem cells and this process of 
specialization is termed differentiation (reviewed in 1). Embryonic stem cells are nearly 
totipotent, meaning they have the ability to differentiate into almost all cell types in the 
human body. For some cell populations, such as lens epithelial cells, neurons, and muscle 
cells, differentiation takes place during embryogenesis, forming mature, functional 
tissues with very low rates of cell turnover in the mature organism (2). Other cell types, 
including keratinocytes, erythrocytes, and monocytes are continuously undergoing self-
renewal and differentiation in adulthood (2). These cell types require the presence of 
undifferentiated precursor cell populations, ready to divide and differentiate as needed. 
As different tissues contain cells with specific and specialized morphologies and 
functions, each cell type has its own distinct differentiation program, and the program 
chosen for the stem cell is dependent on a number of intrinsic and environmental factors 
(3). 
 
The Cell Cycle 
 
In order for cells to enter into a differentiation program they must first arrest 
growth and withdraw from the cell cycle (4). The cell cycle consists of a series of highly 
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regulated events directing a cell through DNA duplication and eventual division into two 
daughter cells (reviewed in 5). The cell cycle can be broken down into four main phases: 
G1, S, G2 and M (Figure 1). Cells that are in the S (synthesis) phase are in the process of 
duplicating their DNA, and therefore will have between 2N and 4N DNA content (5). 
Cells that are in the M phase begin with 4N DNA and split into two daughter cells 
containing 2N DNA each (5). The G phases represent gaps in the cycle between the two 
main events of synthesis and division. Cells in the G1 phase will be in the process of 
Figure 1: The stages of the cell cycle and sites of Cdk/Cyclin regulation. Adapted from 
Schafer, 1998 (5).  
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preparing for DNA synthesis while cells in the G2 phase are readying for mitosis (5). 
Rather than entering into the S phase, cells in G1 can also enter into a non-proliferative 
quiescent stage called G0 (6).  
A cell’s progression through these cell cycle phases is dependent on the activity 
of cyclin-dependent kinases (cdks) and cyclin proteins (see Figure 1) (5). The cdk family 
of proteins are activated at different time points in the cell cycle and allow for 
progression through the cell cycle (5). Cdk activation is absolutely critical for progression 
of the cell cycle and their inhibition has been shown to prevent mitosis (5). While protein 
expression of cdks remains fairly stable throughout the cell cycle, expression of their 
activating proteins, cyclins, changes drastically at different phases (6). The changing 
levels of cyclin protein expression throughout the cell cycle allows for periodic activation 
of cdks (6).  Full activation of the cdk-cyclin complexes requires further phosphorylation 
events at specific residues to induce conformational changes in the complexes (reviewed 
in 6).   
Inhibition of these cell cycle activating proteins is carried out by CDK inhibitors 
(CKIs) which act to either directly bind and inhibit cdks or bind to cdk-cyclin complexes 
to achieve inhibition (6). CKIs consist of two main families of inhibitory proteins: INK4 
proteins and Cip/Kip proteins (6). INK4 proteins, such as p15, p16, p18 and p19, bind 
directly to cdks, preventing their association with and activation by cyclins (6). 
Conversely, the Cip/Kip family of inhibitory proteins, including p21, p27, and p57, bind 
to and inhibit cdk-cyclin complexes (6). Cell cycle arrest can be achieved through 
upregulation of some of these inhibitory proteins. For example, p21 can be activated by 
p53 to inhibit DNA synthesis through the binding of proliferating cell nuclear antigen 
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(PCNA) (6). Clearly, this process is tightly regulated by a number of proteins and 
complexes, and deregulation can lead to uncontrollable and unchecked cell division, such 
as in cancer.   
 
Differentiation and the Cell Cycle 
 
 The onset of differentiation is coupled with a cell’s terminal exit from the cell 
cycle. Differentiation-related factors function not only to induce gene expression of 
proteins required by the mature cell but also act to regulate the transition from 
proliferation to differentiation (7). In order for a cell to arrest growth and begin 
differentiating, cdks and cyclins must be downregulated while inhibitory CKIs must be 
upregulated (7). There is considerable crosstalk between cell cycle regulation and 
differentation and deregulation of the cell cycle can disrupt proper differentiation (8). 
Stimulation by growth factors prevents differentiation and encourages cell proliferation 
while removal of growth signals can induce differentiation (9).  Thus, it is important to 
consider not only differentiation-related factors but also cell cycle regulatory factors 
when studying differentiation.  
 
Myocyte Differentiation  
 
In skeletal muscle, differentiation occurs during embryonic development when 
muscle precursor cells called myoblasts exit the cell cycle and fuse to form 
multinucleated myotubes, which further differentiate into muscle fibres (10). This process 
is tightly regulated by a variety of proteins, hormones, and transcription factors.  
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 During embryogenesis, somite cells forming the dermomyotome (11) receive 
signals to express the transcription factors Pax3 and Pax7, specifying these cells as 
muscle cells (12) (see Figure 2). Pax3/Pax7-expressing progenitor cells initiate the 
expression of myogenic regulatory factors (MRFs) Myf5 and subsequently, MyoD, 
committing the cells to the myogenic program (13). Myf5 and MyoD expressing cells 
expand and proliferate to form myoblasts (10). At this point, MyoD expression halts cell 
proliferation (through enhancement of p21 expression) (14), and induces the expression 
of two other MRFs - myogenin and MRF4 (10). Expression of these regulatory factors 
results in formation of myocytes. Specifically, myogenin is necessary for the terminal 
differentiation of myocytes into multinucleated myotubes (15), which will express late 
differentiation markers such as myosin heavy chain (MHC). At this point, the muscle 
progenitor cells have fully differentiated to form functional, contractile, multinucleated 
myofibers.  
Figure 2: Regulation of myocyte differentiation. Pax3/Pax7 positive cells induce 
expression of MRFs Myf-5 and MyoD, committing these cells to the myogenic lineage. 
Secondary MRFs myogenin and MRF-4 are subsequently activated, resulting in 
transcription of muscle related genes such as myosin heavy chain. Adapted from 
Bloemberg, 2012 (94) 
 6 
MRF expression and activity is regulated by inhibitor of differentiation (Id) 
proteins, that sequester E proteins from MyoD (16,17). E proteins regulate MyoD activity 
by forming activated complexes with MyoD, allowing for transcriptional upregulation of 
muscle-specific genes (17). Other inhibitors include Twist (18), Mist1 (19), MyoR (20) 
and Sharp-1 (21), which all act to inhibit MyoD transcriptional activity. The decline of 
these inhibitory proteins at the induction of differentiation allows for myogenesis to 
proceed.  
 
Apoptosis 
 
Apoptosis is a highly conserved physiological process that is crucial for the 
regulation of tissue development and disease. Like most biological processes, apoptotic 
signaling must be tightly regulated in order to maintain optimal function and health. For 
example, elevated levels of apoptosis have been observed in skeletal muscle during 
aging, as well as in many disease states leading to muscle atrophy, and dysfunction (22). 
Conversely, attenuated apoptotic signaling can lead to improper tissue development and 
cancer (23). Recent evidence has emerged suggesting that apoptotic signaling, a classical 
cell-death mechanism plays a crucial role in cell differentiation. 
 
Caspases 
 
Initiation and execution of apoptosis is carried out primarily by a family of 
proteolytic enzymes called caspases (cysteine-aspartic proteases). Caspases cleave a wide 
variety of specific proteins causing a cascade that results in the stereotypic morphological 
changes associated with apoptosis (DNA fragmentation, plasma membrane blebbing, 
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chromatin condensation) (24). Caspases can be divided into two groups: initiator caspases 
(caspase-8, caspase-9) and effector caspases (caspase-3, caspase-6, caspase-7). Both 
initiator and effector caspases are present in the cell as inactive pro-caspases but the 
method of enzyme activation differs between the two classes (25).  
Initiator caspases are activated through dimerization with high molecular weight 
protein complexes (26). For example, the activation of initiator caspase-9 in response to 
DNA damage involves the release of cytochrome c from the mitochondria, which 
subsequently activates the apoptotic protease-activating factor-1 (APAF-1) apoptosome 
complex (27). This complex then recruits and activates caspase-9, which in turn directly 
activates caspase-3, an effector caspase, through cleavage of the zymogen form of the 
enzyme (27). Thus, in contrast to the initiator caspases, cleavage of the effector caspases 
by the initiator caspases into a small and large catalytic subunit is sufficient for their 
activation (25). The role of caspases in cell death is well defined; however, recent 
research has emerged suggesting that these classical apoptosis-related proteins have roles 
in other cellular processes. 
 
Apoptotic Signaling in Differentiation  
 
One of the cellular processes that apoptotic signaling has been implicated in is 
differentiation. The idea that apoptotic signaling may play a role in the differentiation 
process first arose when it was observed that nuclear degradation (a hallmark of 
apoptosis) is necessary for differentiation in keratinocytes (28), lens epithelial cells (29), 
and erythrocytes (30). Classical apoptotic events such as cytoskeletal reorganization (31), 
activity of matrix metalloproteinases (32), and exposure of extracellular 
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phosphatidylserine residues (33) are necessary for skeletal muscle differentiation. Due to 
the observed similarities between processes, it is likely that the molecules involved in one 
process also play a role in the other. Indeed, research has shown that certain caspases, 
historically cell death proteins, are also important for skeletal muscle differentiation.  
 In 2002, Fernando et al. first demonstrated that myocyte differentiation is 
dependent on caspase-3 activity, and that inhibiting caspase-3 drastically impairs the 
formation of myotubes (34). Since then, more recent studies have supported this finding 
(35), and have implicated initiator caspases in this process. Caspases-8 (36), -9 (37) and -
12 (38,39) have been found to be important in skeletal muscle differentiation, albeit 
through activation of caspase-3.   
 The importance of caspase activity throughout differentiation has been further 
demonstrated through the identification of differentiation-related substrates for caspases. 
For example, Twist can be cleaved by caspase-3 (40), relieving the inhibition on MyoD 
and other pro-myogenic proteins (41). Furthermore, there is evidence to suggest that 
cleavage and activation of caspase-activated DNase (CAD) by caspase-3 is required for 
p21 induction and the subsequent cell cycle exit necessary prior to differentiation (42).  
 Whether a cell undergoes differentiation or death at the hands of caspases is likely 
dependent on the duration and intensity of the enzymatic activity. In skeletal muscle 
differentiation, caspase activation appears to be transient (34), and to a lesser degree than 
what is seen in apoptotic cell death (43,44). The tipping point between caspase activation 
leading to differentiation or apoptosis is also likely due to the increased expression of 
anti-apoptotic proteins early in the differentiation process (45). Consequently, caspases 
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are allowed to perform the remodeling required for differentiation but are inhibited before 
their activation can lead to apoptosis.    
 
Caspase-2 
 
  Previous research in our lab suggests that caspase-2 may also play a role in the 
differentiation process, specifically in skeletal muscle (45). Caspase-2, the most 
physiologically conserved of the caspase enzymes, has proven to be enigmatic for 
researchers. Despite years of study, caspase-2 remains poorly understood in terms of 
modes of activation, target substrates, and physiological functions. Researchers have 
failed to definitively place this enzyme in the apoptotic cascade, as it shares functional 
similarities to both initiator and effector caspases. Similar to effector caspases, caspase-2 
can cleave downstream cellular targets; however, like the initiator caspases, dimerization 
is required in addition to cleavage for full activation of the enzyme (46). Baliga et al 
tested the activity of an uncleavable form of caspase-2 as compared to a wild-type form 
of the enzyme and found that the cleavage defective form was able to retain 
approximately 20% of the enzymatic activity, as long as dimerization had occurred (47). 
Conversely, a cleaved, monomeric form of the enzyme showed no activity whatsoever 
(47). Therefore, similar to caspase-8 and -9, dimerization is a crucial initial step in 
caspase-2 activation. 
 
Caspase-2 Activation 
 
The most widely accepted method of caspase-2 activation involves its recruitment 
to a high molecular weight protein complex (48). Much of the initial work performed in 
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identifying the caspase-2 specific signaling complex was done by Jürg Tschopp and 
colleagues in the late 1990’s.  
Jürg Tschopp first coined the term “CARD” (caspase recruitment domain) when 
he discovered a conserved protein:protein interaction motif present in many caspases and 
caspase adaptor proteins (49). Similar to the other initiator caspases, caspase-2 consists of 
a long, CARD-containing prodomain, as well as a small and large catalytic subunit (50). 
The CARD allows for the recruitment of the enzyme to a larger signaling complex (51). 
In the case of caspase-2, the CARD of caspase-2 binds to the CARD in the adaptor 
molecule RAIDD (RIP-associated Ich-1/Ced-3-homologue protein with a death domain) 
which recruits the enzyme to the signaling platform (52). 
Researchers in Tschopp’s laboratory then identified the role of PIDD (p53 
induced death domain containing protein) in this process (53). Interaction between 
caspase-2 and RAIDD allowed for the recruitment of caspase-2 to PIDD and subsequent 
activation of the apoptotic enzyme (53). PIDD, a p53 induced protein, contains a death 
domain (DD) at the carboxyl terminal as well as a series of leucine-rich repeats (LRRs) at 
the amino terminal (53). LRRs are also present in nucleotide-binding oligomerization 
domain-like (NOD-like) proteins and can function to recognize noxious stimuli resulting 
in inflammasome or NODosome assembly and subsequent caspase-1 or NFκB activation 
(54,55). It is hypothesized that PIDDosome assembly occurs in a similar manner; 
however, researchers have yet to identify molecules that can bind the LRRs in PIDD (56).  
In response to a variety of cellular signals, including genotoxic stress, the DD of 
RAIDD binds to the DD of PIDD and induces caspase-2 activation (46). The PIDDosome 
complex consists of five PIDD DDs and seven RAIDD DDs forming two stacked rings, 
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which can then recruit seven caspase-2 molecules and engage the apoptotic pathway (56). 
It is generally well accepted that caspase-2 induces apoptosis through the cleavage of 
pro-apoptotic Bcl2 family member Bid into its active form tBid. tBid acts on the 
mitochondria to induce cytochrome c release, which in turn activates caspase-9 resulting 
in apoptosis (57).   
Interestingly, other experiments have demonstrated caspase-2 activation in the 
absence of PIDD and RAIDD (58), suggesting that other modes of activation may exist. 
PIDD KO mice showed no impairment in caspase-2-mediated apoptosis (58) and heat 
shock appears to activate caspase-2 in a p53-independent (and therefore PIDDosome-
independent) manner (59). Using T and B cell lines, researchers in Germany found 
caspase-2 docked to an alternative signaling complex, CD95 DISC (death-inducing 
signaling complex), most commonly associated with caspase-8 (60). These researchers 
did not, however, find measurable levels of RAIDD at the DISC, implying the presence 
of an unidentified adaptor protein with both a CARD and DD that can recruit caspase-2 
to the DISC (60). It is interesting to note that the recruitment of caspase-2 to the DISC 
does not necessarily induce downstream apoptosis in the absence of caspase-8 (60). This 
would imply a redundant, amplification function of caspase-2 in conjunction with 
caspase-8 in inducing CD95-mediated apoptosis. Another possible mechanism of 
caspase-2 activation includes dimerization of caspase-2 molecules and subsequent 
autoproteolysis, triggered by the K+ efflux that is seen in response to bacterial pore-
forming toxins (61). Collectively, this data shows that the precise mode of activation of 
caspase-2 is not fully understood, and future research would be beneficial in better 
defining these mechanisms. 
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Caspase-2 and Apoptosis 
 
A variety of evidence has demonstrated a major role for caspase-2 in the apoptotic 
pathway. Kumar and colleagues showed that caspase-2 is highly expressed during 
embryonic development, a stage where widespread cell death occurs (62). Furthermore, it 
has been shown that caspase-2 is activated early in the apoptotic cascade (63,64), and that 
overexpression of caspase-2 induces cell death in mammalian cells (62,65).   
 The majority of research implicates caspase-2 in DNA-damage induced cell death 
(66). A number of researchers suggest a possible primary mechanism for caspase-2 
apoptotic induction involving both the intrinsic and extrinsic pathways of apoptosis 
(52,60,67). In response to DNA damage, p53 induces activation of the Fas receptor (also 
referred to as CD95 receptor) on the cell membrane (66). Evidence for the activation of 
caspase-2 at this complex was discussed previously. FADD (Fas-associated protein with 
death domain) then recruits and activates caspase-8 and also caspase-2 (66). Both 
caspase-8 and caspase-2 are able to then cleave Bid into activated tBid, which induces 
mitochondrial outer membrane permeablization and cytochrome c release (66). 
Alternatively, a study by Sidi et al demonstrated the involvement of caspase-2 in an 
ATM/ATR-dependent cell death pathway (68).  ATM (ataxia telangiectasia mutated) is a 
kinase that is activated by the presence of double-stranded breaks in DNA (68). This 
pathway appears to be activated in response to DNA damage in the absence of p53 by 
checkpoint kinase-1 (68). What is interesting about this mechanism is the lack of 
involvement of p53 and apoptotic molecules such as Bcl-2 or caspase-3 (68). 
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Caspase-2 in the Cell Cycle and DNA Damage Response 
 
In contrast to the rest of the caspase family, which are exclusively found outside 
the nucleus, caspase-2 has been found to be present in both the cytosol and the nucleus of 
cells. Researchers discovered a nuclear localization signal in the long prodomain of 
caspase-2 that allowed for importin-mediated transport of caspase-2 to the nucleus (69). 
Studies using immunofluorescence of endogenous caspase-2 (70,71) and imaging of 
GFP-caspase-2 complexes (72) indicate that caspase-2 is primarily a nuclear protein. 
Conversely, a number of studies have also shown caspase-2 localized to the cytosol (73), 
Golgi (74), and mitochondria (75). Nonetheless, the nuclear localization of caspase-2 is 
consistent with recent research that has shown it likely plays a role in the DNA damage 
response, the cell cycle, and tumour suppression.  
It has been proposed that a determining factor in the function of caspase-2 is the 
level of cellular damage that is present. As discussed above, when levels of DNA and 
cellular damage are high, caspase-2 is activated through the PIDDosome (or possibly 
other alternative mechanisms) to induce apoptosis (76). At lower levels of damage, 
however, it is likely that caspase-2 can function as a cell cycle checkpoint regulator and 
play a role in DNA repair.  
A study by Mendelsohn et al has provided some evidence for a regulatory role of 
caspase-2 in the cell cycle (77). Researchers found a direct association between cyclin D3 
and caspase-2 in that cyclin D3 expression increased the amount of active caspase-2 (77). 
The authors suggest that an interaction between cyclin D3 and caspase-2 may act to 
stabilize the protease, connecting cell cycle mechanisms to cell death mechanisms (77). 
Further research has demonstrated that phosphorylation of caspase-2 by cyclin-dependent 
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kinase 1 (CDK1)-cyclin B1 inhibits caspase-2 activation during normal mitosis, and 
protein phosphatase 1 (PP1) dephosphorylates the enzyme during interphase (78). Failure 
to inactivate caspase-2 through phosphorylation during mitosis results in the death of the 
cell (78). Low levels of PP1 activity are seen during normal mitosis; however, cellular 
insult such as DNA damage can induce activation of PP1, alleviating the suppression of 
caspase-2 and inducing cell death (78). Collectively, this data suggests that caspase-2 
may function as a cell cycle checkpoint when low levels of damage occur and that 
caspase-2 plays an apoptotic role with higher levels of DNA damage.  
Further evidence of a cell cycle regulatory role for caspase-2 is its proposed 
ability to positively regulate the cell cycle inhibitory protein, p21 (79). Researchers found 
that knocking down caspase-2 increased rates of cell proliferation and reduced p21 
expression in HCT116 cells, while p53 levels remained unchanged (79). Furthermore, 
overexpressing caspase-2 resulted in increased p21 protein levels (79). The authors 
suggest that this p21 regulatory function of caspase-2 is actually the protease’s primary 
function; however, the precise method with which caspase-2 is regulating p21 could not 
be elucidated (79).   
 In a study comparing wild type MEFs to caspase-2 deficient MEFs, researchers 
found evidence for a role of caspase-2 in the DNA damage response (80). Caspase-2 
knockout MEFs were shown to proliferate faster than wild type MEFs and also avoid 
cellular senescence (the point at which a cell no longer divides (81)) (80). Due to the 
enhanced proliferation of the cells, researchers then considered the effect caspase-2 
deficiency had on DNA damage by measuring the presence of micronuclei, which can 
arise due to DNA breaks or chromosomal fragments (80). Caspase-2 knockout cells had 
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consistently higher levels of micronuclei compared to their wild type counterparts (80). 
Furthermore, cells lacking caspase-2 showed delayed and reduced DNA damage repair, 
as a response to ionizing radiation treatment (80). Finally, cells deficient in caspase-2 
showed enhanced chromosomal abnormalities including aneuploidy (an abnormal 
number of chromosomes) (80). Overall, this study points to an important role of caspase-
2 in the DNA damage response.  
 
 
Caspase-2 in Differentiation 
 
Given these findings, it is possible that caspase-2 has a role in skeletal muscle cell 
differentiation. Indeed, previous work in our lab has shown transient upregulation of 
caspase-2 at the onset of skeletal muscle differentiation (45). Interestingly, this activation 
of caspase-2 appears to occur prior to the activation of caspase-3, which is essential for 
myogenesis. Caspase-2 has been shown to directly activate caspase-3 through binding of 
their pro-domains (82); thus, it is possible that upregulation of caspase-2 is contributing 
to caspase-3 activation in skeletal muscle differentiation. Furthermore, research using 
aged caspase-2 knockout mice found that loss of caspase-2 greatly reduced caspase-3 
activation in the liver (83). Alternatively, the cell cycle regulatory properties of caspase-2 
present an interesting and unique possible function for caspase-2 in regulating 
differentiation through moderating cell cycle exit.  
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Purpose 
 
Previous research has demonstrated a role for caspases in myocyte differentiation. 
Given the findings from Bloemberg and Quadrilatero (94) showing caspase-2 activation 
at the onset of differentiation, as well as evidence that caspase-2 may function in cell 
cycle regulation, it is possible that caspase-2 activation early on in differentiation is 
required for cells to enter into the differentiation program, and that this activation may 
contribute either directly or indirectly to the previously observed caspase-3 activation in 
the early stages of myocyte differentation.  
 
Therefore, the main objectives of my thesis project were to: 
1) Characterize the activity of caspase-2 throughout skeletal muscle differentiation  
2) Determine the effect of a lack of caspase-2 on caspase-3 activation and skeletal 
muscle differentiation 
3) Determine the subcellular localization of caspase-2 throughout the differentiation 
process 
 
Experiment 1: Caspase-2 activity throughout differentiation 
 
An in vitro model was used to determine the activity of caspase-2 in skeletal 
muscle differentiation. C2C12 mouse skeletal myoblasts were maintained in an 
undifferentiated, proliferative state and subsequently induced to differentiate into mature 
myotubes via incubation in media containing low growth factor levels, as previously 
performed in our lab (45). Cells were collected at various time points throughout the 
differentiation process to be used for experimental analyses. Activity of caspases-2 and -3 
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throughout the differentiation process were assessed using fluorometric assays. Cell cycle 
regulation across differentiation was assessed by immunoblotting for p21 and via flow 
cytometry cell cycle analyses. Protein levels of myogenin, MyoD, and Myosin were 
quantified along with fluorescent microscopy to analyze the degree of differentiation in 
these cells.  
 
Experiment 2: Differentiation in the absence of caspase-2 
 
 To better elucidate the role of caspase-2 in the myocyte differentiation process, 
caspase-2 protein content was knocked down via shRNA. Western blotting for caspase-2 
protein content was used to ensure efficient caspase-2 knockdown (KD) in cells. The 
impact of caspase-2 KD on cell cycle regulation was assessed by comparing flow 
cytometry cell cycle analyses between KD and controls as well as measuring p21 content 
throughout differentiation. The effect of caspase-2 KD on myocyte differentiation was 
assessed via immunoblotting for myogenic markers myogenin, MyoD, and Myosin in the 
caspase-2 KD cells. Finally, morphology of caspase-2 KD cells was analyzed using 
fluorescent microscopy.   
 
Experiment 3: Subcellular Localization of caspase-2 during differentiation 
 
 In order to better determine the role of caspase-2 in differentiation, the subcellular 
localization of caspase-2 was assessed at various time points in differentiation. C2C12 
cells were collected at early time points in differentiation, when caspase-2 is shown to be 
most active. Cells were processed into nuclear and extranuclear/nuclear-free fractions and 
caspase-2 content was measured in each compartment. Subcellular localization of p21 
 18 
was also measured in the fractions in order to provide insight on the precise function of 
caspase-2 activation in differentiation. 
 
Hypotheses 
It was hypothesized that: 
1) Caspase-2 activity would increase early in the differentiation process, prior to 
caspase-3 activation. This would be noted by: 
a. A transient spike in caspase-2 activity, occurring immediately prior to 
caspase-3 activity increase, measured by fluorometric assay 
b. Protein content of cell cycle regulator p21 would increase immediately 
upon induction of differentiation  
2) Caspase-2 knockdown would impair cell cycle regulation and myocyte 
differentiation. This would be observed in the KD cells as: 
a. A decrease in p21 content 
b. Dysregulated cell cycle characteristics 
c. Lower levels of caspase-3 activation  
d. A decrease in differentiation markers: cell fusion, myosin, myogenin 
3) Caspase-2 would be localized to the nucleus during differentiation  
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Methods 
 
Cell Culture 
 
C2C12 mouse skeletal myoblasts (ATCC) were cultured in growth media (GM) 
consisting of low-glucose Dulbecco’s Modified Eagles Medium (DMEM; Hyclone, 
ThermoScientific) containing 10% fetal bovine serum (FBS; Hyclone, ThermoScientific) 
with 1% penicillin/streptomycin (Hyclone, ThermoScientific) and plated in 100mm, 6-
well and/or 12-well polystyrene cell culture dishes. Cells were seeded at a density of 
650/cm
2
. Media was aspirated, cells washed with 37°C phosphate buffered saline (DPBS) 
and fresh warmed GM was added every 1-2 days. As previously performed in our lab, 
cells were allowed to proliferate until they reached 80-90% confluence at which point 
differentiation was induced by switching from GM to a differentiation media (DM), 
consisting of DMEM containing 2% horse serum (Hyclone, ThermoScientific) and 1% 
penicillin/streptomycin (45).   
 
Isolation and Determination of Total Protein Content 
 
Cells were isolated at various time points throughout differentiation, depending 
on the experiment being performed. The time points collected included: prior to 
differentiation (day 0; D0), and 6 hours (D0.25), 12 hours (D0.5), day 1 (D1), day 1.5 
(D1.5), day 2 (D2), day 3 (D3), day 5 (D5), day 7 (D7) following induction of 
differentiation. Isolation of cells was done by aspirating the media, washing cells 
thoroughly with warmed PBS, and then trypsinizing (0.25% trypsin with 0.2g/L EDTA; 
ThermoScientific). Whole cell lysates were generated by adding lysis buffer (20mM 
HEPES, 10mM NaCl, 1.5mM MgCl, 1mM DTT, 20% glycerol, and 0.1% Triton-X100, 
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pH 7.4) with protease inhibitors (Complete Cocktail; Roche Diagnostics) to cells and 
sonicating the mixture. Total protein content of cell lysates was measured by the BCA 
protein assay method.  
 
Fluorometric Caspase Activity Assay  
 
To assess activity of caspase-2 and caspase-3 during differentiation, the 
fluorogenic substrates Ac-VDTTD-AFC (21
st
 Century Biochemicals) and Ac-DEVD-
AMC (Enzo Life Sciences) were used, respectively. The uncleaved form of the substrates 
is weakly fluorescent; however, proteolytic cleavage by their respective caspase results in 
highly fluorescent products. Previous research regarding caspase-2 activity employed the 
use of the Ac-VDVAD-AMC substrate. This substrate has been shown to be cleaved by 
caspase-3 with almost equal efficiency. The Ac-VDTTD-AFC substrate used here is 
cleaved far more efficiently by caspase-2 than by caspase-3 and therefore provides an 
improved characterization of caspase-2 activity (84). Cells were isolated as previously 
described (using lysis buffer without protease inhibitors added) and incubated with the 
fluorogenic substrates in duplicate in black 96 well plates (Grenier Bio One). A Synergy 
H1 Microplate Reader (BioTek) was used to measure fluorescence. Caspase activity was 
normalized to total protein content, and is expressed as fluorescence intensity (arbitrary 
units)/mg protein.  
 
Immunoblotting 
 
As previously performed in our lab (85), equal amounts of protein were loaded 
and separated on 7-12% SDS-PAGE gels, and transferred to PVDF membranes. 
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Membranes were blocked for 1 hour at room temperature with 5% milk-Tris-buffered 
saline-Tween 20 (milk-TBS-T). Membranes were subsequently incubated overnight at 
4°C with primary antibodies against myogenin, myosin (Developmental Studies 
Hybridoma Bank) MyoD, p21 (Santa Cruz Biotechnology), caspase-2, Histone H2B 
(Millipore), caspase-3, actin (Sigma-Aldrich), and MnSOD (Stressgen). After washing in 
TBS-T, membranes were incubated in the corresponding horseradish peroxidase (HRP)-
conjugated secondary antibody (Santa Cruz Biotechnology) for 1 hour at room 
temperature. After washing with TBS-T, Clarity
TM
 Western Enhanced 
Chemiluminescence detection reagent (Bio Rad) was applied to the membranes for 1 
minute and images were taken with the ChemiGenius 2 Bio-Imaging System (Syngene). 
The molecular weight of each protein was estimated using Precision Plus Protein
TM 
Kaleidoscope
TM
 Prestained Protein Standards (Bio-Rad Laboratories). To confirm equal 
loading and transfer, expression levels were normalized to actin as a loading control.  
 
Fluorescent Microscopy 
 
 In order to assess cell morphology, fluorescent microscopy was used to visualize 
nuclei and expression of myosin. Cells were grown on glass coverslips in culture dishes 
and removed at various time points throughout differentiation. After washing 2 x 5min 
with PBS, cells were fixed for 10 minutes in 4% formaldehyde-PBS and washed. Cells 
were then permeablized with 0.5% Triton-X100 for 10 minutes, washed with PBS, and 
blocked with 10% goat serum in PBS for 30 minutes. Cells were then incubated in the 
primary antibody against myosin (MF20; Developmental Studies Hybridoma Bank) for 1 
hour, washed with PBS, and then incubated in the appropriate fluorescent-conjugated 
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secondary antibody (Alexa Fluor 488; Molecular Probes) for 1 hour. After washing with 
PBS, cells were counterstained with DAPI nuclear stain (Molecular Probes) for 5 minutes 
and washed with PBS. Coverslips were mounted with Prolong Gold Antifade Reagent 
(Molecular Probes) and visualized with an Axio Observer Z1 fluorescent microscope 
(Carl Zeiss).  
 
Cell Fusion Index 
 
 Fluorescent microscopy images were used to assess the degree of fusion 
throughout differentiation.  All nuclei within ten randomly chosen fields were counted.  
Cell fusion index was determined by the number of nuclei in multi-nucleated cells 
divided by the total number of nuclei, resulting in a fusion percentage per field.  
 
Knockdown of caspase-2 via shRNA 
 
 Caspase-2 protein expression was knocked down in cultured myoblasts using 
shRNA.  Caspase-2 shRNA plasmids were generously provided by Dr. Jonas Nilsson; 
University of Gothenburg (86). Plasmids were transfected into myoblasts at 50-60% 
confluence using Lipofectamine 2000 (Life Technologies) similar to previous work 
performed in our lab (87). Lipofectamine 2000 and plasmid shRNA were separately 
diluted in Opti-MEM (Gibco) and incubated at room temperature for 5 minutes. These 
mixtures were then added together and complexed at room temperature for 5 minutes. 
After washing cells twice with Opti-MEM, cells were incubated in the transfection 
mixture for 6 hours at 37°C. Transfection media was then aspirated and, after washing 
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twice with PBS, cells were incubated overnight in GM. Stable clones were obtained using 
puromycin.  Caspase-2 knockdown was assessed via western blotting.  
 
 
Flow Cytometry Analysis of Cell Cycle 
 
 In order to assess the impact of differentiation and caspase-2 knockdown on cell 
cycle properties, cells were collected at the following time points in differentiation: day -
1 (D-1; approximately 50% confluent), day 0 (D0; just prior to induction of 
differentiation), day 0.5 (D0.5), day 1 (D1), and day 2 (D2) following induction of 
differentiation. Cells were harvested via trypsinization and centrifuged at 100g for 5 
minutes. After removing the supernatant, the pellet was resuspended in 1mL of PBS and 
centrifuged a second time at 100g for 5 minutes. The supernatant was again removed and 
the cells were resuspended in 100μL of PBS. To fix the cells, 1mL of ice-cold 70% 
reagent-grade ethanol was added to each sample dropwise over the course of 
approximately one minute. Cells were stored at 4°C for at least 24 hours. To prepare the 
samples for flow cytometry, cells were centrifuged at 1000g for 5 minutes. After 
removing the supernatant, samples were washed twice with PBS. 100μL of RNAse was 
added followed by 400μL of propidium iodide (PI) solution (50μg/mL in 0.1% Triton-X 
PBS). Samples were then incubated at room temperature in the dark for 30 minutes at 
which point PI fluorescence was measured using flow cytometry (FACSCalibur, BD 
BioSciences). Resultant data was analyzed using Cell Quest Pro Software (BD 
Biosciences). 
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Fractionation 
 
C2C12 cells were separated into nuclear and extra-nuclear fractions via 
differential centrifugation, as previously performed in our lab (45).  Previous research 
regarding caspase-2 subcellular localization has shown that lysing of cells for 
experimental purposes artificially redistributes nuclear caspase-2 to the cytoplasm, thus 
preventing accurate localization information from these fractions (88). The same 
researchers found that pre-incubation of cells prior to harvesting with N-ethylmaleimide 
(NEM) prevented this redistribution and allowed for detection of nuclear caspase-2 via 
western blotting (88) (Appendix Figure 1). Thus, cells were treated for 10min with 
7.5mM NEM as described previously (88). Cells were then washed with PBS, trypsinized 
for 5 minutes and centrifuged at 1000g for 5 minutes. After aspirating the supernatant, the 
resulting pellet was resuspended in lysis buffer as described above and incubated on 
ice/vortexed on and off for 10 minutes. Samples were centrifuged again at 1000g for 5 
minutes. The supernatant was collected, centrifuged again at 1000g for 5 minutes and 
kept as the extra-nuclear fraction. The pellet was resuspended and centrifuged twice in 
lysis buffer at 1000g for 5 minutes and kept as the nuclear fraction. Fraction purity was 
assessed by immunoblotting for MnSOD (extra-nuclear) and Histone H2B (nuclear).  
 
Statistical Analyses 
 
All results are presented as means ± standard error of mean (SEM). Experiment 1 
was analyzed by one-way ANOVA compared to time point D0, with the exception of cell 
cycle analyses, which were compared to time point D-1. Experiment 2 was analyzed by t-
tests between groups at each time point. Experiment 3 was analyzed via t-tests between 
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nuclear and extra-nuclear fractions at each time point and one-way ANOVA across 
differentiation for changes in nuclear procaspase-2 expression. Statistical significance 
was set at p<0.05 with p<0.10 considered a trend. All statistical analyses were performed 
with Graph Pad Prism Statistical Software.   
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Results 
Cell Cycle Regulation in Skeletal Muscle Cell Differentiation  
Cell cycle characteristics throughout differentation were assessed by measuring PI 
fluorescence in cells harvested at time points representing rapidly dividing cells (D-1 
time point), confluent cells (D0) and cells beginning to differentiate (D0.5 – D2).  C2C12 
cells will most rapidly divide when they are subconfluent and will slow down 
proliferation once they begin to reach confluence. At D-1, approximately 54.7% of cells 
were in the G0/G1 phase (Figure 3A & 3B). The remaining 43.3% of cells were in the S 
and G2/M phases at this time point. (Figure 3A & 3B).  As the cells began to reach 
confluence, cell cycle withdrawal was observed, as noted by a significant increase in 
G0/G1 cells (p<0.05, Figure 3A & 3B). At this point, approximately 69.2% of cells were 
in G0/G1 while 30.8% of cells were still in S or G2/M (Figure 3A & 3B). Once 
differentiation was induced, the amount of cells in G0/G1 continued to significantly 
increase (p<0.05) and by D1, approximately 92.5% of cells were in this phase (Figure 3A 
& 3B). Cell cycle properties were further analyzed by measuring protein content of p21, a 
cell cycle regulator involved in cell cycle exit and growth arrest. Western blotting for p21 
throughout differentiation revealed a 3-fold increase in p21 content at D1 and D2 
(p<0.05) (Figure 3C & 3D). By D3, p21 content began to decrease but still showed a 
trend towards significance from day 0 (p<0.10, Figure 3C & 3D). When cells reached 
terminal differentation (D5 and D7), p21 content returned to day 0 levels (Figure 3C & 
3D). 
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Figure 3: Cell cycle regulation in C2C12 myoblast differentiation.  
A) Representative flow cytometry histograms of propidium iodide fluorescence, 
indicating cell cycle stage. B) Graphical representation of histograms shown in (A) 
highlighting observed differences in cell cycle phases as differentiation progresses.  C) 
Representative immunoblot of whole-cell p21 protein expression across differentiation 
with actin loading control. D) Quantification of p21 protein expression levels 
normalized to actin loading control. *p<0.05 compared to day 0; #p<0.10 compared to 
day 0 (mean ± SEM, n=3 independent experiments). 
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Skeletal Muscle Cell Differentiation Characteristics 
 
As cells began to differentiate, MyoD protein decreased consistently from D0, 
with an 88% reduction by D7 (p<0.05, Figure 4). Expression of myogenin rapidly 
increased from D0 to D1, peaking at D2 with a nearly 60-fold increase from D0 (p<0.05, 
Figure 4).  After this point, myogenin protein began to decrease and by D7, was no 
longer significantly different from D0. Expression of myosin protein, which is indicative 
of the degree of differentiation, was essentially negligible at D0 and was drastically 
increased   by   D7   (p<0.05, Figure 4).   Similarly, fluorescent   microscopy  revealed  a 
A 
B 
Figure 4: Expression of differentiation 
markers during C2C12 myoblast 
differentiation. A) Representative 
immunoblots of whole-cell MyoD, 
myogenin, and myosin expression across 
differentiation with actin loading 
control. B) Quantification of MyoD, 
myogenin and myosin expression levels 
normalized to loading control. *p<0.05 
compared to day 0; 
#
p<0.10 compared to 
day 0 (mean ± SEM, n=3 independent 
experiments). 
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complete lack of myosin positive cells at D0, with levels steadily increasing as myotubes 
developed (p<0.05, Figure 5). Quantification of the amount of nuclei within 
multinucleated cells revealed an increase in cell fusion as differentiation progressed 
(p<0.05, Figure 5). By D5, 53% of nuclei were contained in multinucleated cells (Figure 
3). 
 
Caspase Activity Throughout Differentiation 
 
Activity of caspase-2 and caspase-3 throughout differentation was measured using 
fluorometric enzyme  assays. Within 12  hours  of  inducing  differentiation,  caspase-2  
B 
A 
Figure 5: C2C12 cell morphology during 
myoblast differentiation. A) Fluorescent 
microscopy images depicting cell 
morphology at various stages of 
differentiation. Nuclei are stained blue 
(DAPI) and myosin heavy chain is stained 
green (Alexa Fluor 488). Bar represents 
50μm. B) Quantification of fusion index 
calculated by dividing the number of nuclei 
in multi-nucleated fibres by the total number 
of nuclei in ten randomly chosen 
microscopic fields. *p<0.05 compared to 
day 0 (mean ± SEM, n=3 independent 
experiments). 
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activity more than doubled, with activity reaching a 2.3-fold increase by D1 (p<0.05, 
Figure 6). Activity remained significantly elevated until D2 (p<0.05) after which point it 
began to return to D0 levels (Figure 6). Similarly, caspase-3 activity rapidly increased 
upon induction of differentiation, reaching a 2.8-fold increase by D1 (p<0.05, Figure 6). 
Like caspase-2, caspase-3 activity steadily tapered off after D2 and returned to near-D0 
levels by D7 (Figure 6). 
 
 
Knockdown of Caspase-2 in C2C12 cells 
 
To elucidate the role of caspase-2 in skeletal muscle cell differentiation, C2C12 
cells were stably transfected with caspase-2 shRNA (casp2 KD) or scramble shRNA 
Figure 6: Caspase activity throughout differentiation. Caspase activity was assessed 
using fluorogenic substrates specific to each caspase. Activity is normalized to total 
protein content and expressed relative to day 0 levels. *p<0.05 compared to day 0 (mean 
± SEM, n=3 independent experiments).  
 
 
 
Figure 6: Caspase activity throughout differentiation. Caspase activity was assessed 
using fluorogenic substrates specific to each caspase. Activity is normalized to total protein 
content and expressed relative to day 0 levels. *p<0.05 compared to day 0 (mean ± SEM, 
n=3 independent experiments). 
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(scram). Multiple casp2 KD clones were collected and tested for comparison. The clone 
used for all subsequent experiments was found to have similar cell cycle and 
differentiation characteristics as other casp2 KD clones (data not shown). Procaspase-2 
was approximately 94% reduced in the casp2 KD cells compared to the scram cells 
(Figure 7A & 7B). Scram cells, conversely, were found to have similar procaspase-2 
levels (Figure 7A & 7B) and exhibited similar cell cycle properties, differentiation 
 
A B 
C 
Figure 7: Knockdown of caspase-2 
in C2C12 cells. A) Representative 
immunoblot of procaspase-2 protein 
expression in C2C12, scram, and casp2 
KD cells. B) Quantification of 
procaspase-2 protein expression in 
C2C12, scram, and casp2 KD cells 
normalized to actin loading control. C) 
Caspase-2 activity in scram and casp2 
KD cells throughout differentiation. 
†p<0.05 between groups at individual 
time points (mean ± SEM, n=3 
independent experiments). 
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properties and morphology as control C2C12 cells, therefore, subsequent results will 
compare between scram cells and casp2 KD cells within time points. Consistent with a 
dramatic decrease in procaspase-2 content, activity of caspase-2 throughout 
differentiation was significantly reduced in casp2 KD cells compared to scram cells 
(p<0.05, Figure 7C). Specifically, scram cells had significantly more caspase-2 activity 
than casp2 KD cells at D0.5, D1 and D1.5 (Figure 7C). In order to assess the impact of 
off-target effects of shRNA transfection on the cells’ ability to differentiate, clones that 
had been transfected with the casp2 KD plasmid but did not exhibit protein knockdown 
were plated and induced to differentiate (Appendix figure 2A). By D6, visual observation 
of the cells revealed fused myotubes similar to control cells (Appendix figure 2B). 
Similarly, western blotting for myogenin and myosin revealed essentially normal 
differentiation characteristics (Appendix figure 2C). Collectively, these data suggest the 
subsequent effects of casp2 KD on differentiation are due to a lack of caspase-2 and this 
protein’s critical role in skeletal muscle cell differentiation. 
 
Cell Cycle Properties in the Absence of Caspase-2 
 
Previous literature has suggested a role for caspase-2 in cell cycle regulation. 
Given these findings, along with the changes observed in cell cycle properties as 
differentiation progresses, we decided to measure cell cycle characteristics of caspase-2 
KD cells at the induction of differentiation. Interestingly, casp2 KD cells showed higher 
percentages of cells in G0/G1 across all time points compared to scram cells (p<0.05) and 
decreased levels of cells in S and G2/M (p<0.05, Figure 8A and 8B). These data would 
suggest an increase in growth arrest in the casp2 KD cells compared to the scram cells. 
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A 
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B 
D Figure 8: Cell cycle regulation in the absence of 
caspase-2. A) Representative histogram outputs 
of PI fluorescence, indicating cell cycle stage in 
scram and casp2 KD cells. B) Graphical 
representation of histograms shown in (A). C) 
Representative immunoblots of whole-cell p21 
protein expression across differentiation in scram 
and casp2 KD cells with actin shown as a loading 
control. D) Quantification of p21 protein 
expression levels normalized to loading control. 
†p<0.05 compared to scram, #p<0.10 compared to 
scram (mean ± SEM, n=3 independent 
experiments). 
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Conversely, p21 protein expression was reduced 23-fold at D1 and remained significantly 
reduced until D5 in casp2 KD cells compared to scram (p<0.05, Figure 8C & 8D). As 
p21 has been implicated in the cell cycle exit necessary for differentiation to begin, these 
data appear contradictory. Regardless, the overall cell cycle data show a deregulation of 
the cell cycle in the absence of caspase-2. 
B 
A 
Figure 9: Expression of differentiation markers in scram and casp2 KD cells after 
inducing differentiation. A) Representative immunoblots of whole-cell MyoD, 
myogenin, and myosin expression in scram and casp2 KD cells with actin shown as a 
loading control. B) Quantification of MyoD, myogenin and myosin expression levels in 
scram and casp2 KD cells, normalized to loading control. †p<0.05 compared to scram; 
(mean ± SEM, n=3 independent experiments). 
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A 
B 
Figure 10: Morphology of scram and casp2 KD cells throughout differentiation.  A) 
Fluorescent microscopy images depicting scram and casp2 KD cell morphology at 
various stages of differentiation. Nuclei are stained blue (DAPI) and myosin heavy chain 
is stained green (Alexa Fluor 488). Bar represents 50μm. B) Quantification of fusion 
index calculated by dividing the number of nuclei in multi-nucleated fibres by the total 
number of nuclei in ten randomly chosen microscopic fields. Casp2 KD cells exhibited 
severely impaired differentiation. †p<0.05 compared to scram (mean ± SEM, n=3 
independent experiments). 
 36 
Skeletal Muscle Cell Differentiation in the Absence of Caspase-2 
 
In experiment 1, caspase-2 activity was shown to transiently increase early on in 
differentiation, suggesting a possible role for caspase-2 in this process. Using the casp2 
KD cells and scram cells, we induced differentiation and measured differentiation 
markers in both groups. As discussed previously, scram cells were shown to exhibit 
similar characteristics as control C2C12 cells. Thus, in these experiments, comparisons 
were simply made between scram and caspase-2 KD cells at each time point. MyoD 
protein expression was not significantly different between groups (Figure 9A & 9B). 
However, myogenin expression was dramatically reduced in casp2 KD cells compared to 
scram at D1 and all time points thereafter (p<0.05, Figure 9A & 9B). Similarly, casp2 
KD cells had virtually undetectable levels of myosin at all time points, which was 
significantly different between groups from D2 until D7 (p<0.05, Figure 9A & 9B). 
Consistent with these data, fluorescent microscopy revealed a dramatic increase in 
myosin expression in scram cells at D2 and D5 and no detectable myosin in casp2 KD 
cells at any time point (Figure 10A).  By D5, 61.2% of nuclei in scram cells were located 
within multinucleated cells (Figure 10A & 10B). Conversely, at the same time point, 
100% of nuclei in casp2 KD cells remained unfused and did not express myosin (Figure 
10A & 10B). 
 
Caspase-3 Activity in the Absence of Caspase-2 
 
A transient spike in caspase-3 activity early on in differentiation has been 
consistently shown to be required for skeletal muscle cell differentiation. As we observed 
abrogated differentation in the casp2 KD cells, we assessed the impact the  
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knockdown had on caspase-3 activity. Caspase-3 enzyme activity was decreased by 40% 
at D1 in casp2 KD cells compared to scram cells (p<0.05, Figure 11A) and remained 
significantly decreased in casp2 KD cells at D5 and D7 (p<0.05, Figure 11A). 
  A 
B 
C Figure 11: Caspase-3 activity and protein 
expression in scram and casp2 KD cells 
throughout differentiation. A) Caspase-3 
activity throughout differentiation in scram 
and casp2 KD cells. B) Representative 
immunoblots of procaspase-3 content 
throughout differentiation in scram and casp2 
KD cells normalized to loading control.  
C) Quantification of procaspase-3 protein in 
scram and casp2 KD cells expressed relative 
to loading control. †p<0.05 compared to 
scram; #p<0.10 compared to scram (mean ± 
SEM, n=3 independent experiments). 
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Furthermore, data from the D0.5 and D3 time points revealed a trend towards 
significance between the two groups (p<0.10, Figure 11A). These effects were not 
explained by a difference in procaspase-3 protein content in the casp2 KD cells as there 
were few differences between groups (Figure 11B & 11C). Thus, caspase-3 activity but 
not content appear to be affected by a lack of caspase-2.  
 
Subcellular Localization of Caspase-2 During Differentiation 
 
In order to better elucidate the role of caspase-2 in differentiation, C2C12 cells 
were collected at early time points in differentiation, when caspase-2 has been shown to 
be most highly active. Cells were then processed into nuclear and extra-nuclear (or 
nuclear-free) fractions and immunoblotted for caspase-2 content. Expression of 
procaspase-2 was found almost exclusively in the nuclear fraction and was essentially 
absent in the extra-nuclear fraction at all time points (p<0.05, Figure 12A & 12B) 
suggesting a nuclear localization of caspase-2 throughout differentiation. Interestingly, 
nuclear expression of procaspase-2 decreased significantly at D1 and D2 compared to D0 
(p<0.05, Figure 12A & 12B). According to previous caspase assay experiments, caspase-
2 is most highly active from approximately 12-48 hours into differentiation. It was 
initially hypothesized that this decrease in nuclear procaspase-2 would result in a 
corresponding increase in extra-nuclear procaspase-2; however, this export was not 
observed. It is now hypothesized that the decrease in nuclear procaspase-2 is associated 
with a corresponding increase in nuclear cleaved caspase-2, thus suggesting that caspase-
2 is being activated in the nucleus during differentiation rather than being exported into  
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B 
Figure 12: Subcellular localization of caspase-2 and p21 during differentiation.  
A) Representative immunoblots of procaspase-2 and p21 in nuclear (N) and extra-nuclear (E) 
fractions during the early stages of differentiation. MnSOD and Histone H2B are used as purity 
controls as they are found exclusively in their respective fractions (MnSOD in extranuclear; 
Histone H2B in nuclear). B) Quantification of procaspase-2 and p21 protein expression in nuclear 
and extra-nuclear fractions during the early stages of differentiation. Both procaspase-2 and p21 
are predominantly localized to the nucleus throughout this process. Expression of procaspase-2 
decreases at day 1 and day 2 compared to day 0 levels. *p<0.05 compared to day 0; †p<0.05 
compared to nuclear; #p<0.10 compared to nuclear (mean ± SEM, n=3 independent experiments). 
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the cytosol and activated. Preliminary experiments have supported this hypothesis 
(Appendix Figure 3). 
As shown in experiment 1, immunoblotting for p21 expression throughout 
differentiation revealed a dramatic increase in p21 protein early on in differentiation as 
the cells are exiting the cell cycle and entering into the differentiation program. 
Furthermore, in experiment 2, p21 expression was dramatically reduced in the casp2 KD 
cells compared to scram. According to literature, caspase-2 plays a role in p21 activation; 
thus, it is possible that caspase-2 is exerting its role in differentiation through the 
activation of p21 early on in differentiation. Since we observed a nuclear localization of 
caspase-2 during differentiation, we determined if p21 was also localized to the nucleus 
during differentiation. Indeed, p21 expression was significantly higher in the nuclear 
fraction than in the extra-nuclear fraction at D0.25, D0.5 and D2 (p<0.05, Figure 12A & 
12B) and trended towards significance at D0 and D1 (p<0.10, Figure 12A & 12B). Thus, 
p21 appears to remain in the nucleus throughout differentiation. Collectively, these data 
are in line with the hypothesis that caspase-2 may be inducing p21 expression early on in 
differentiation. 
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Discussion 
 
The main focus of this study was to comprehensively examine the involvement of 
caspase-2 in skeletal muscle cell differentiation. As it stands, little is concretely known 
about caspase-2 in terms of functions, activation methods, and target substrates. Evidence 
exists for the interplay between apoptotic signaling mechanisms and differentiation with 
regards to caspase-3 (34), -8 (36), -9 (37), and -12 (39); however, only one study has 
previously identified a role for caspase-2 in this process. Previous work in our lab by 
Bloemberg & Quadrilatero (45) found that caspase-2 activity transiently increases early 
on in differentiation, appearing to increase even prior to caspase-3 activation. The present 
study aimed to better elucidate the role that caspase-2 may be playing in skeletal muscle 
differentiation. In order to test the hypothesis that caspase-2 activity is required for proper 
myocyte differentation, we measured caspase-2 activity in differentiating C2C12 murine 
myoblasts using a newer and more specific caspase-2 substrate. Furthermore, we 
produced stable caspase-2 KD clones and observed the differences in cell cycle and 
differentiation markers between the casp2 KD cells and scram control cells. Finally, we 
performed cellular fractionation to determine subcellular localization of caspase-2 
throughout differentiation.  
The results of this study demonstrate a critical role for caspase-2 in skeletal 
muscle cell differentiation. We confirmed the prior findings by Bloemberg and 
Quadrilatero (45) using a more specific substrate for caspase-2 activity. Furthermore, 
knock down of caspase-2 protein in C2C12 cells drastically impaired differentiation and 
resulted in a dysregulation of the cell cycle. Finally, we showed that caspase-2 remains 
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localized to the nucleus throughout differentiation, alluding to its potential role in 
regulating differentiation via cell cycle exit.  
 
Caspase-2 Activity Transiently Increases at the Onset of Differentiation 
  
In order to lay the foundation for subsequent experiments, we aimed to confirm 
proper differentation characteristics in the C2C12 cells. We assessed cell cycle profiles, 
myogenic regulatory factor expression levels and cell morphology and fusion events in 
differentiating C2C12 cells.  Using flow cytometry detection of propidium iodide 
fluorescence, cell cycle stage was assessed as cells began to differentiate. Consistent with 
literature (4,7–9), induction of differentiation coincided with cell cycle exit as noted by 
an increase in the proportion of G0/G1 cells and a decrease of cells in the S and G2/M 
phases (Figure 3A & 3B). Within 24 hours, approximately 92.5% of cells had entered 
into the nonproliferative G0/G1 phase of the cell cycle (Figure 3A & 3B). In accordance 
with cell cycle profiles, protein expression levels of p21 increased rapidly upon induction 
of differentiation (Figure 3C & 3D). As previously mentioned, p21 is a CDK inhibitor 
which can bind to and inhibit cdk-cyclin complexes 1 and 2 and plays a well established, 
required role in cell cycle exit prior to the onset of differentiation (14,89,90).  Overall, 
our results are in accordance with the literature in regards to cell cycle characteristics at 
the onset of differentiation.   
Protein expression levels of MyoD, myogenin, and myosin throughout 
differentiation were also consistent with the literature (reviewed in 10). At the onset of 
differentiation, MyoD levels decreased consistently from day 0 until day 7 (Figure 4A & 
4B). As cells began to differentiate, myogenin protein levels increased rapidly, peaking at 
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day 2 and returning to near-basal levels by day 7 (Figure 4A & 4B). As cells reached 
terminal differentiation, myosin expression and cell fusion events both increased 
dramatically (Figure 4A & 4B; Figure 5A & 5B). Collectively, cell cycle, MRF, and 
microscopy data confirm proper differentiation in the C2C12 cells.  
The vast majority of studies that have focused on the relationship between 
apoptotic signaling and myocyte differentiation have not measured caspase-2 activity, 
instead focusing on caspase-3 (34,91–93), -8 (36), and -9 (92,93). One study that did 
attempt to assess caspase-2 activation in differentiating C2C12 cells did not find 
measurable increases in the activated form of caspase-2; however, these researchers used 
only immunoblotting for the cleaved form of the enzyme and did not specify which 
antibody they used (37). Therefore, it is possible that the disparity in results between our 
study and the previously mentioned study are due to methodological differences. No prior 
studies have used the new, more specific caspase-2 substrate (VDTTD) to assess caspase-
2 activation in differentiating cells. Consistent with previous findings in our lab (94) 
which used the former caspase-2 substrate (VDVAD), caspase-2 activity, measured with 
the VDTTD substrate, transiently increased very quickly upon induction of 
differentiation in C2C12 cells (Figure 6). The VDVAD substrate first arose in 1997 when 
researchers demonstrated efficient cleavage of VDVAD containing peptides by caspase-
2; however, caspase-3 was shown to cleave the same peptide sequence with comparable 
kinetics (95). Other studies have had similar results (96,97), yet many researchers 
continue to use VDVAD substrates.  The improved VDTTD substrate was developed by 
a group of researchers in Australia in 2014 (84). Using a yeast transcriptional reporter 
system, the authors were able to identify the minimal specificity of caspase-2 and employ 
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this data to create an appropriate fluorogenic substrate (84). In contrast to the oft-used 
VDVAD substrate, the VDTTD substrate has proven to be cleaved far more efficiently by 
caspase-2 than -3 (84). While this newly defined substrate is not absolutely caspase-2 
specific, it is a far more promising tool than the commonly used VDVAD peptide 
sequence. Thus, the increased specificity of the VDTTD substrate adds credibility to our 
lab’s previous findings with regards to caspase-2 activity in myocyte differentiation. In 
the present study, caspase-3 activity also increased rapidly and activity of both enzymes 
remained elevated until day 2, at which point activity levels began to decrease (Figure 6). 
By day 7, activity levels of caspase-2 and -3 were no longer statistically different from 
day 0 (Figure 6). Caspase activity in the C2C12 cells coincided with the onset of 
differentiation and as cells reached terminal differentiation, caspase activity returned to 
basal levels. 
The most well-known and accepted function of caspase-2 is its role in apoptosis; 
its ability to cleave Bid to form tBid and cause subsequent release of pro-apoptotic 
factors from the mitochondria (57,98,99). Previous work from our lab, however, indicates 
that this mitochondrial-mediated apoptotic pathway is not involved in the differentiation 
process (45). Therefore, this classical apoptotic role of caspase-2 is likely not the means 
by which caspase-2 is affecting differentiation. In the present study, caspase-2 activity 
appeared to increase around the same time as caspase-3 activity (Figure 6). This is in 
contrast to Bloemberg & Quadrilatero’s findings that caspase-2 activity increased just 
prior to caspase-3 activation (94). However, our results indicated that caspase-2 appears 
to peak and plateau by 12 hours (Figure 6). In contrast, caspase-3 activity continues to 
rise after 12 hours, peaking between 24 and 36 hours into differentiation (Figure 6). Thus, 
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due to the rapid and transient nature of enzymatic activity, it is possible that caspase-2 is 
indeed becoming active prior to caspase-3. In order to better examine the temporal 
profiles of caspase-2 and -3 at the onset of differentiation, future studies should collect 
more frequent time points between 0 and 48 hours to determine precise activation times.  
If caspase-2 activity is in fact increasing prior to caspase-3 activation, it could be 
suggested that caspase-2 may be responsible for activating caspase-3 in differentiation. 
Indeed, previous work has provided evidence for caspase-2’s ability to activate caspase-3 
directly through binding of the prodomain (82). The cell cycle regulatory function of 
caspase-2 may suggest, however, that caspase-2 is playing a different role in 
differentiation, one that is more upstream of caspase-3 activation.  
 
 
Caspase-2 KD Cells Display Dysregulated Cell Cycle Profiles and Impaired 
Differentiation 
 
 In order to explore the precise role of caspase-2 in differentiation, we produced 
shRNA-mediated caspase-2 KD clones in C2C12 cells. Cells transfected with casp2 
shRNA plasmids displayed dramatically reduced caspase-2 content, measured via 
immunoblotting (Figure 7A & 7B), and caspase-2 activity, measured via fluorogenic 
enzyme assays (Figure 7C).  The enzyme assay results from differentiating C2C12 cells 
suggested a requirement for caspase-2 activation in skeletal muscle differentiation. We 
further investigated this theory by comparing cell cycle profiles and differentiation 
characteristics between casp2 KD cells and scram control cells.  
Due to the abundance of evidence demonstrating a role for caspase-2 in cell cycle 
regulation, we first compared cell cycle properties in casp2 KD cells to our scram control 
cells. Interestingly, flow cytometry data revealed a significant difference in the 
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proportion of cells in G0/G1 phase at all time points between groups in that casp2 KD 
cells had a higher proportion of cells in the G0/G1 phase (Figure 8A & 8B). 
Correspondingly, casp2 KD cells had a smaller proportion of cells in S and G2/M phase at 
almost every time point (Figure 8A & 8B). These results would imply that casp2 KD 
cells are arresting earlier than scram cells, which appears to be in contrast to literature 
showing that caspase-2 knockout MEFs proliferate faster than wild-type MEFs and avoid 
cellular senescence (80); however, the difference in cell line used may contribute to the 
disparity in results that was observed. A role for caspase-2 in cell cycle control has been 
shown in previous literature, implicating the protease in G2/M checkpoint control 
(80,100), a time when DNA is assessed for mutations and cells are prevented from 
undergoing mitosis if significant mutations are present (6). In one study, caspase-2 
knockout MEFs were able to overcome G2 arrest much more easily than wild type MEFs 
in response to infrared radiation (80). Similarly, we observed a decrease in proportion of 
cells in G2/M phase in the casp2 KD condition compared to the scram condition (Figure 
8A & 8B), suggesting that in the absence of caspase-2, cells may be moving through the 
G2/M phase unchecked and unregulated. Aberrations in cell cycle checkpoint control 
leading to accumulations of damaged DNA has been shown to result in aneuploidy 
(abnormal number of chromosomes) and genomic instability (101,102); an effect that has 
been observed in caspase-2 deficient MEFs (80). Examination of our cell cycle data from 
day 1 revealed that casp2 KD cells had a more heterogeneous distribution of cells in 
G0/G1 compared to scram (Figure 8A). According to previous literature, G0/G1 peaks with 
wide coefficients of variation often contain aneuploid cell populations (103); thus, it is 
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possible that the wider G0/G1 peak observed in the casp2 KD cells at day 1 is caused by 
aberrant DNA checkpoint control resulting in abnormal DNA content and aneuploidy.  
 While we did observe an increased proportion of casp2 KD cells in the G0/G1 
phase, immunoblotting also revealed a lack of p21 induction in casp2 KD cells, which is 
typically needed for cell cycle exit. Protein levels of p21 were dramatically reduced in 
casp2 KD cells compared to scram at almost all time points after the onset of 
differentiation (Figure 8C & 8D).  This is not particularly surprising, given the evidence 
that caspase-2 is required for p21 expression (79); however, it does appear to be in 
contrast with our cell cycle data. Nonetheless, it is clear that casp2 KD cells demonstrate 
irregularities in cell cycle control.   
 Given the interplay that exists between cell cycle regulation and differentiation, it 
is not surprising that differentiation was dramatically impaired in casp2 KD cells. 
Fluorescent microscopy revealed a complete lack of myotube formation at any time point 
in the casp2 KD cells, while scram cells appeared to differentiate normally (Figure 10). 
Likewise, myosin protein increased dramatically until day 7 in scram cells while casp2 
KD cells displayed virtually undetectable levels of myosin at any time point (Figure 9A 
& 9B). Previous work in our lab has also demonstrated impaired C2C12 differentiation 
with a lack of caspase-2 activity (94). Treatment of cells with caspase-2 inhibitor 
(VDVAD-CHO) decreased myosin expression and cell fusion events in a dose-dependent 
manner (94). Chemical inhibition also resulted in a reduction of caspase-3 activity (94). 
Similarly, we observed a dramatic abrogation of caspase-3 activation, while protein 
levels of procaspase-3 remained unchanged (Figure 11), indicating that caspase-2 
knockdown affected caspase-3 processing and activation. There is evidence to suggest 
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that caspase-2 can directly activate caspase-3 (82); however, we are unable to conclude 
with our results whether caspase-3 activity repression is directly due to the knockdown or 
instead due a lack of upstream differentiation events that are prevented by the caspase-2 
knockdown.  Nevertheless, caspase-3 has been shown to be critical for myocyte 
differentiation; therefore, it is not surprising that we observed a dramatic impairment in 
this step of the pathway in our KD cells.  
Furthermore, Bloemberg et al found that while lower doses (30μm) of caspase-2 
inhibitor did not appear to impact myogenin induction, higher doses (75μm) significantly 
inhibited myogenin in differentiation-induced C2C12 cells (94). In the present study, we 
also observed a dramatic impairment in myogenin protein expression in the casp2 KD 
cells. While scram cells displayed normal myogenin induction at the onset of 
differentiation, casp2 KD cells had very little myogenin protein content and showed no 
increase early on in differentiation (Figure 9A & 9B). Perhaps unsurprisingly, MyoD 
protein content was not affected by the protein knockdown, as there were no significant 
differences in MyoD content between groups at any time point (Figure 9A & 9B). This 
would suggest that MyoD is upstream of caspase-2 activation in differentiation. Previous 
research has implicated MyoD in inducing p21 expression in myoblasts in order to cause 
cell cycle exit (4,8,14,89); however, given that MyoD expression was not affected by 
casp2 KD but p21 expression was, it is possible that caspase-2 is responsible for inducing 
p21 expression independently of MyoD. Indeed, previous work has shown a need for 
caspase-2 in p21 expression in response to DNA damage (79). Furthermore, p21 
expression has been shown to be crucial for proper myocyte differentiation (90,104). In 
1999, Zhang and colleagues observed profound defects in skeletal muscle differentiation 
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in p21/p57 KO mice and posited that these CKI proteins are controlling differentiation at 
the myogenin step (i.e. downstream of MyoD; 101).  More recently, researchers have 
demonstrated that p21 KO mice had greatly impaired muscle regeneration in response to 
bupivacaine-induced muscle injury (90). Exactly where p21 fits into the temporal 
landscape of myocyte differentiation is difficult to establish. Some researchers place p21 
activation downstream of myogenin (105); some believe it is a parallel occurrence to 
myogenin induction (104), and others suggest that myogenin is translocated to the 
nucleus only after proliferation has ceased, putting myogenin activation after p21 
activation (106).  Thus, at this point it is difficult to determine if and how caspase-2 may 
be regulating myogenin during differentiation. Collectively, these results suggest that 
caspase-2 is likely acting downstream of MyoD and upstream of p21, myogenin, and 
caspase-3 during myocyte differentiation.  
 
 
Caspase-2 Remains Localized to the Nucleus Throughout Differentiation 
 
In order to better understand the precise role that caspase-2 is playing in 
differentiation, we assessed the subcellular localization of both caspase-2 and p21 
throughout differentiation. We posited that knowing the location of these proteins might 
help to shed light on where caspase-2 is acting in this complex process.  Our results 
indicated that caspase-2 retained its nuclear localization throughout differentiation, with 
no apparent cytosolic translocation (Figure 12A & 12B). Interestingly, expression levels 
of procaspase-2 decreased in the nuclear fraction around 12 hours – 2 days of 
differentiation (Figure 12A & 12B). As this is the timeframe that caspase-2 is most 
active, a decrease in expression levels initially appears counter-intuitive. A corresponding 
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increase in extra-nuclear expression levels would explain this nuclear decrease; however, 
this export from the nucleus was not observed (Figure 12A & 12B). Intriguingly, 
preliminary work from our lab indicated a corresponding increase in nuclear cleaved 
caspase-2 levels (Appendix Figure 3), indicating activation of caspase-2 occurring within 
the nucleus itself. Subcellular localization of caspase-2 has been widely debated, with 
some researchers suggesting it is primarily cytosolic, mitochondrial, or nuclear (69-75). 
Our work suggests that caspase-2 is primarily nuclear in C2C12 myocytes and it remains 
in the nucleus as differentiation proceeds (Figure 12A & 12B; Appendix Figure 3). That 
being said, subcellular localization of the enzyme could very well differ between cell 
types and processes. The enzyme’s localization provides intriguing information as to 
caspase-2’s role in differentiation. If caspase-2 were located in the cytosol, it is likely that 
it would be playing a similar role to the other apoptotic proteases (caspase-3, -8, -9) in 
differentiation. For example, research has implicated a need for caspase-3-mediated 
cleavage-induced activation of promyogenic kinase MST1 (34). Furthermore, Twist, an 
inhibitor of differentiation, has been identified as a substrate for cleavage-induced 
inactivation by caspase-3 (40). Initiator caspases -8 (36) and -9 (37) have also been 
implicated in skeletal muscle cell differentiation, albeit through activation of the 
executioner caspase-3. In contrast to these other caspases, caspase-2 is uniquely found in 
the nucleus suggesting that it plays a myogenic role quite distinct to the other members of 
its family; its nuclear localization would suggest a cell cycle regulatory role, as we have 
hypothesized.  
Furthermore, we also found p21 localized to the nucleus throughout 
differentiation. Human p21 is primarily found in the nucleus however; it has been 
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reported in other cellular compartments (107). The localization of p21 is predominantly 
regulated through post-translational modifications such as phosphorylation and 
ubiquitination (reviewed in 104). As previously discussed, research has shown that 
caspase-2 is required for p21 expression; however, investigators were unable to 
definitively determine how regulation was occurring, but speculated that it may be 
through inhibition of microRNAs that are known to prevent p21 translation (79). 
Alternatively, it is possible that caspase-2 is indirectly impacting the activation of p21 by 
affecting its degradation. A variety of studies have shown that nuclear p21 can be 
targeted for proteasomal degradation by the E3 ubiquitin ligase Mdm2 (108,109). 
Interestingly, additional research has shown that caspase-2 can cleave and inactivate 
Mdm2, specifically in the context of Mdm2-mediated degradation of p53 (110); however, 
a similar mechanism could be at play with p21 (i.e. caspase-2 inactivates Mdm2, 
preventing Mdm2 from targeting p21 for degradation).  Indeed, our immunoblotting 
results for p21 expression in scram cells and casp2 KD cells could be explained by a 
increased degradation of p21 in the absence of caspase-2 (Figure 8C & 8D). Due to the 
fact that Sohn et al (79) could not elucidate the mechanism with which caspase-2 was 
contributing to p21 expression, it is possible that caspase-2 is acting indirectly on p21 via 
Mdm2 inhibition and, consequently, decreased protein degradation.  
As previously mentioned in the context of C2C12 differentiation, evidence 
suggests that myogenin is localized to the cytoplasm in proliferating cells and is 
translocated to the nucleus only after proliferation has ceased (106). As p21 has been 
shown to be required for cell cycle exit in differentiation, this would place myogenin 
translocation after p21 induction. Our results indicated a dramatic impairment of protein 
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expression for both p21 and myogenin in casp2 KD cells, both of which would have 
significant effects on myocyte differentiation (Figure 8C & 8D; Figure 9). As the 
literature is inconclusive with respect to the timeline of p21 and myogenin activation, the 
signaling cascade of events is currently unclear. However, if myogenin is indeed 
translocated to the nucleus only after cells have arrested proliferation, then p21 is the 
more likely primary target of caspase-2 in this process, and the observed impairment in 
myogenin induction is probably an indirect effect. Taken together, the co-localization of 
both caspase-2 and p21 in the nucleus throughout differentiation along with the dramatic 
decrease in p21 expression in casp2 KD cells suggests that caspase-2 is contributing to 
the induction of p21expression during differentiation. 
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Summary and Conclusions 
 
 For years, researchers have struggled to pin down a singular, primary role for the 
enigmatic protease caspase-2. Unlike its family members, caspase-2 is difficult to fit into 
the classical apoptotic pathway and its unique nuclear localization is consistent with 
findings that it functions in cell cycle regulation, DNA damage response, and tumour 
suppression. It is clear that caspase-2 is a multifaceted enzyme with a variety of cellular 
roles. The main goal of this study was to investigate the role that caspase-2 might be 
playing in cellular differentiation. The results of this study highlight three main points: 1) 
caspase-2 is temporarily activated early on during myoblast differentiation, 2) myoblasts 
lacking caspase-2 do not differentiate, and 3) caspase-2 remains localized to the nucleus 
throughout myoblast differentiation. Given the findings that p21 expression is 
dramatically reduced in casp2 KD cells, as well as the suggestion that the primary role of 
caspase-2 is likely its ability to regulate p21, we propose that the role of caspase-2 in 
differentiation is to contribute to the activation of p21 to allow for cell cycle exit and 
subsequent differentiation. While this theory requires further investigation, the results of 
this study indicate a novel, critical role for caspase-2 in skeletal muscle cell 
differentiation.   
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Limitations 
 
shRNA transfection as a means of knocking down protein expression is widely 
used in literature; however, stably transfecting a plasmid into a cell line requires the 
integration of a piece of foreign DNA into the cell’s genome, which can result in off 
target effects depending on where the plasmid has been incorporated (111). As a means 
of controlling for these potential effects, scramble cell clones were transfected, isolated 
and passaged in the same way as KD clones; however, it is still possible that some of the 
observed effects of caspase-2 KD on differentation were due to the transfection process 
and not the protein knockdown. To further attempt to control for this possibility, clones 
that were transfected with the casp2 KD plasmid but did not display measurable protein 
KD were induced to differentiate. These “non-KD” clones appeared to differentiate 
normally and showed normal myogenin and myosin protein expression (Appendix figure 
2). Furthermore, a separate casp2 KD clone displayed similar differentiation impairment 
and cell cycle dysregulation (data not shown). Therefore, while the possibility still exists 
that some of the observed changes in differentiation are due to off-target effects, we are 
confident that our overall results are indicative of the importance of caspase-2 protein 
expression in myocyte differentiation.  
 A major barrier to caspase-2 research is the lack of caspase-2 specific tools to 
monitor enzymatic activity. VDVAD containing peptides are efficiently cleaved by 
caspase-2 but caspase-3 is shown to also cleave the peptide sequence with comparable 
kinetics (95). Other studies into caspase-2 substrates have found similar results (96,97), 
yet many researchers continue to use VDVAD substrates, claiming they are caspase-2 
specific. It is clear that there is a need for more selective tools for caspase-2 activity and 
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inhibition; substrates that can be cleaved effectively by caspase-2 only. More recently, 
researchers were able to develop a better caspase-2 substrate. In contrast to the commonly 
used VDVAD-derived substrates, Ac-VDTTD-AFC has been shown to be cleaved far 
more efficiently by caspase-2 than -3 (84). Thus, we employed the use of the VDTTD 
substrate in this study. While this newly defined substrate is not absolutely caspase-2 
specific (84), it is a far more promising tool than the commonly used VDVAD peptide 
sequence. Therefore, although we cannot definitively say that the observed fluorescence 
is due to caspase-2 activity, we can be more confident that we are measuring caspase-2 
and not caspase-3 activity with this new substrate.  
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Future Directions 
 
Although the results of this study indicate that caspase-2 is critically important for 
C2C12 differentiation, further is required to elucidate the precise activation methods for 
caspase-2 in this process. The nuclear localization of caspase-2 does provide some insight 
into how it may be activated (i.e. likely not through the PIDDosome). Knocking down 
some key potential activators of caspase-2 (Cyclin D3, p53 etc.) via shRNA or CRISPR 
and observing how these knockdowns impact caspase-2 activation in differentiation may 
aid in better understanding this important pathway.  
The results of this study suggest that caspase-2 may be exerting its effect on 
differentiation through contributing to the activation of p21 early on in differentiation. In 
order to definitively provide causal evidence for this activation, future studies should 
attempt to rescue the observed phenotype in the caspase-2 KD cells.  If reintroducing p21 
expression and activation into the KD cells attenuates the effects of the KD, this potential 
link between caspase-2 and p21 would be even more compelling. Increasing p21 
expression has been identified as a possible method of arresting proliferation in cancer 
cells (107). For example, histone deacetylase (HDAC) inhibitors are being employed in 
studies to de-repress p21 (112,113) and proteasome inhibitors are being tested as a means 
of reducing protein degradation of p21 (114). It would be of interest to test out drugs in 
the casp2 KD cells and assess if any rescuing of the phenotype is observed. Furthermore, 
if caspase-2 is in fact contributing to p21 activation via cleavage and inactivation of 
Mdm2, it would be interesting to determine protein levels of Mdm2 in the absence of 
caspase-2, and further investigate how this may be impacting p21 expression. It is 
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possible that inhibiting Mdm2 activity would prevent degradation of p21 and improve 
differentiation in the absence of caspase-2; however, this remains to be determined.  
This study provides evidence for a critical role of caspase-2 in C2C12 
differentiation in vitro. Future studies should aim to replicate these results in vivo. While 
caspase-2 knockout (KO) mice appear to develop muscle normally, it is possible that 
compensatory mechanisms are at play in embryonic development. It would be interesting 
to employ a caspase-2 transgenic KO mouse line and induce skeletal muscle injury to 
determine if caspase-2 is important in muscle cell regeneration via satellite cell 
differentiation. Another possible approach to circumventing the effects of compensatory 
mechanisms in vivo would be to use a tamoxifen inducible caspase-2 KO mouse line to 
introduce protein KO in the adult animal.  
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Appendix Figure 1: Validating NEM pretreatment for fractionation. Cells were 
either pretreated for 10 minutes with n-ethylmaleimide (NEM) or not pretreated (NT) 
prior to harvesting for fractionation. NT cells expressed exclusively extra-nuclear 
procaspase-2 while NEM treatment prevented this artifactual redistribution in the 
pretreated cells. MnSOD and CuZnSOD are located exclusively in the extra-nuclear 
fraction while Histone H2B is found only in the nuclear fraction. Fraction purity was 
confirmed with these control proteins. 
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Appendix Figure 2: Differentiation 
testing of nonKD clones. Cells that were 
transfected with caspase-2 KD plasmid but 
did not exhibit knockdown appear to 
differentiate normally. A) Immunoblots of 
caspase-2 content in C2C12 cells and 
nonKD clones. B) Light microscope 
images of nonKD clones at day 6 of 
differentiation. C) Immunoblots of 
myogenin and myosin protein expression at 
various stages of differentiation in nonKD 
clones.  
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Appendix Figure 2: Differentiation testing 
of nonKD clones. Cells that were transfected 
with caspase-2 KD plasmid but did not exhibit 
knockdown appear to differentiate normally. 
A) Immunoblots of caspase-2 content in 
C2C12 cells and nonKD clones. B) Light 
microscope images of nonKD clones at day 6 
of differentiation. C) Immunoblots of 
myogenin and myosin protein expression at 
various stages of differentiation in nonKD 
clones.  
 
 72 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3: Expression of nuclear cleaved caspase-2 during the early 
stages of differentiation. Protein expression of cleaved caspase-2 appears to be 
increased at days 0.5, 1 and 2 compared to day 0. This increase seems to correspond 
with the decrease in nuclear procaspase-2 observed in experiment 3. 
